<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808505</url>
  </required_header>
  <id_info>
    <org_study_id>ATB200-08</org_study_id>
    <nct_id>NCT04808505</nct_id>
  </id_info>
  <brief_title>Rossella: A Study to Evaluate the Safety, PK, Efficacy, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to &lt;18</brief_title>
  <official_title>An Open-label Study to Evaluate the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to &lt; 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD,&#xD;
      and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and&#xD;
      ERT-naïve pediatric subjects with classic IOPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with the composite endpoint at the end of Stage 1 for Cohort 2 and Cohort 3</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Glycogen Storage Disease Type II Infantile Onset</condition>
  <arm_group>
    <arm_group_label>Cipaglucosidase Alfa/Miglustat -treated ERT-experienced subjects experiencing clinical decline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cipaglucosidase Alfa/Miglustat treated ERT-naïve subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Approved rhGAA-treated ERT-naive subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cipaglucosidase alfa (ATB200)</intervention_name>
    <description>Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsules</description>
    <arm_group_label>Cipaglucosidase Alfa/Miglustat -treated ERT-experienced subjects experiencing clinical decline</arm_group_label>
    <arm_group_label>Cipaglucosidase Alfa/Miglustat treated ERT-naïve subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat (AT2221)</intervention_name>
    <description>Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsules</description>
    <arm_group_label>Cipaglucosidase Alfa/Miglustat -treated ERT-experienced subjects experiencing clinical decline</arm_group_label>
    <arm_group_label>Cipaglucosidase Alfa/Miglustat treated ERT-naïve subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects who are aged &lt; 18 years at screening (For Cohort 1), 0 to &lt;6&#xD;
             month (For Cohort 2 &amp;3)&#xD;
&#xD;
          2. Confirmed diagnosis of classic IOPD&#xD;
&#xD;
          3. Subjects must have experienced a clinical decline based on their current approved&#xD;
             rhGAA dose and frequency (For Cohort 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject received any investigational drug or any investigational biologic for Pompe&#xD;
             disease within 30 days or 5 half-lives of the therapy or treatment, whichever is&#xD;
             longer, before screening.&#xD;
&#xD;
          2. Subject requires invasive ventilation (eg, tracheostomy) or respiratory assistance as&#xD;
             defined in study protocol&#xD;
&#xD;
          3. Subject has received any gene therapy at any time.&#xD;
&#xD;
          4. Subject who is CRIM-negative and has not received prophylactic immunomodulation (For&#xD;
             Cohort 1)&#xD;
&#xD;
          5. Subject with high and sustained antibody titers as defined in study protocol (For&#xD;
             Cohort 1)&#xD;
&#xD;
          6. Subject has any prior history of certain condition or any intercurrent illness as&#xD;
             defined in study protocol&#xD;
&#xD;
          7. Subject has a hypersensitivity to any of the excipients in cipaglucosidase alfa or&#xD;
             miglustat&#xD;
&#xD;
          8. Female subject is pregnant (or intends to get pregnant) or breastfeeding at screening&#xD;
             (For Cohort 1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>For Site</last_name>
    <phone>215-921-7600</phone>
    <email>PompeSiteInfo@amicusrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For Patient</last_name>
    <phone>215-921-7600</phone>
    <email>patientadvocacy@amicusrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

